Our data reveal that the activation of VEGF/VEGFR is significantly impaired in the absence of CD146, suggesting that anti-VEGF and anti-CD146 adjunct therapies would have a cumulative effect on inhibiting tumor angiogenesis. The gene discussed is VEGFA; the disease is neoplasm.